Skip to main content

Table 3 Incidences of treatment-related adverse eventsa after single-agent CPT treatment in 27 patients with RRMM

From: Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Adverse event All gradesb Grade 3/4c
Overall adverse events 24 (88.9) 10 (37.0)
Fever 13 (48.1) 0 (0.0)
AST elevation 13 (48.1) 5 (18.5)
ALT elevation 12 (44.4) 2 (7.4)
Leukopenia 7 (25.9) 3 (11.1)
Rash 4 (14.8) 0 (0.0)
Neutropenia 4 (14.8) 3 (11.1)
Thrombocytopenia 3 (11.1) 2 (7.4)
Blood bilirubin elevation 2 (7.4) 1 (3.7)
Creatinine elevation 2 (7.4) 0 (0.0)
Upper respiratory infection 2 (7.4) 0 (0.0)
Uric acid elevation 1 (3.7)d 1 (3.7)
  1. Only those toxicities deemed possibly, probably, or definitely related to the treatment are included in the table. Note: a patient may have had more than one adverse event
  2. AST aspartate aminotransferase, ALT alanine aminotransferase
  3. aAdverse events were assessed according to the Common Toxicity Criteria for Adverse Events. Data are presented as number of patients followed by percentage in the parentheses
  4. bAdverse event reported in at least 5% of the treated patients
  5. cAll patients with grade 3 or 4 adverse events
  6. dAlthough uric acid elevation occurred in only 1 patient (<5%), this adverse event was listed because it was grade 3